Form 8-K - Current report:
SEC Accession No. 0001193125-24-060883
Filing Date
2024-03-06
Accepted
2024-03-06 17:25:53
Documents
17
Period of Report
2024-03-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d808358d8k.htm   iXBRL 8-K 32359
2 EX-1.1 d808358dex11.htm EX-1.1 228006
3 EX-5.1 d808358dex51.htm EX-5.1 7381
7 GRAPHIC g808358g0306092642617.jpg GRAPHIC 2717
  Complete submission text file 0001193125-24-060883.txt   460034

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA akro-20240305.xsd EX-101.SCH 2849
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE akro-20240305_lab.xml EX-101.LAB 17993
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akro-20240305_pre.xml EX-101.PRE 11260
18 EXTRACTED XBRL INSTANCE DOCUMENT d808358d8k_htm.xml XML 3653
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38944 | Film No.: 24727154
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)